TD Asset Management Inc. Decreases Position in Pfizer, Inc. (PFE)

TD Asset Management Inc. cut its holdings in shares of Pfizer, Inc. (NYSE:PFE) by 1.3% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 5,055,962 shares of the biopharmaceutical company’s stock after selling 66,956 shares during the period. TD Asset Management Inc. owned about 0.30% of Pfizer worth $169,830,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Tdam USA Inc. lifted its position in Pfizer by 0.9% during the second quarter. Tdam USA Inc. now owns 298,329 shares of the biopharmaceutical company’s stock valued at $10,032,000 after purchasing an additional 2,744 shares during the period. Baker Ellis Asset Management LLC lifted its position in Pfizer by 6.8% during the second quarter. Baker Ellis Asset Management LLC now owns 38,593 shares of the biopharmaceutical company’s stock valued at $1,296,000 after purchasing an additional 2,468 shares during the period. Beach Investment Management LLC. acquired a new position in Pfizer during the second quarter valued at $5,214,000. Peak Asset Management LLC lifted its position in Pfizer by 26.2% during the second quarter. Peak Asset Management LLC now owns 43,188 shares of the biopharmaceutical company’s stock valued at $1,451,000 after purchasing an additional 8,969 shares during the period. Finally, Novare Capital Management LLC lifted its position in Pfizer by 2.8% during the second quarter. Novare Capital Management LLC now owns 210,839 shares of the biopharmaceutical company’s stock valued at $7,082,000 after purchasing an additional 5,826 shares during the period. Institutional investors own 69.01% of the company’s stock.

Shares of Pfizer, Inc. (PFE) opened at $35.55 on Friday. The company has a market cap of $210.89 billion, a PE ratio of 14.18, a PEG ratio of 2.45 and a beta of 1.01. The company has a current ratio of 1.34, a quick ratio of 1.06 and a debt-to-equity ratio of 0.58.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.02. Pfizer had a net margin of 18.69% and a return on equity of 25.67%. The company had revenue of $13.17 billion during the quarter, compared to analysts’ expectations of $13.17 billion. During the same quarter in the prior year, the company earned $0.61 EPS. Pfizer’s revenue was up .9% compared to the same quarter last year. analysts predict that Pfizer, Inc. will post 2.59 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 1st. Investors of record on Friday, November 10th will be paid a dividend of $0.32 per share. The ex-dividend date of this dividend is Thursday, November 9th. This represents a $1.28 annualized dividend and a yield of 3.60%. Pfizer’s dividend payout ratio is presently 79.01%.

A number of research analysts recently issued reports on PFE shares. UBS Group AG (USA) restated a “buy” rating and set a $38.00 target price on shares of Pfizer in a research report on Monday, July 31st. Cowen and Company set a $43.00 target price on shares of Pfizer and gave the company a “buy” rating in a research report on Monday, July 10th. Sanford C. Bernstein set a $39.00 target price on shares of Pfizer and gave the company a “buy” rating in a research report on Monday, July 17th. BMO Capital Markets reiterated a “buy” rating and issued a $37.00 price objective on shares of Pfizer in a research report on Wednesday, September 6th. Finally, Zacks Investment Research upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $40.00 price objective for the company in a research report on Tuesday, October 3rd. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and thirteen have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $38.35.

In related news, insider Alexander R. Mackenzie sold 15,000 shares of the company’s stock in a transaction dated Monday, August 7th. The shares were sold at an average price of $33.50, for a total transaction of $502,500.00. Following the completion of the sale, the insider now owns 151,474 shares of the company’s stock, valued at approximately $5,074,379. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Alexander R. Mackenzie sold 7,350 shares of the company’s stock in a transaction dated Thursday, August 31st. The shares were sold at an average price of $34.00, for a total transaction of $249,900.00. Following the sale, the insider now directly owns 132,124 shares of the company’s stock, valued at approximately $4,492,216. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 389,621 shares of company stock valued at $13,298,598. 0.06% of the stock is owned by corporate insiders.

TRADEMARK VIOLATION NOTICE: “TD Asset Management Inc. Decreases Position in Pfizer, Inc. (PFE)” was originally posted by Community Financial News and is owned by of Community Financial News. If you are viewing this article on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark legislation. The correct version of this article can be read at https://www.com-unik.info/2017/11/04/td-asset-management-inc-decreases-position-in-pfizer-inc-pfe.html.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

What are top analysts saying about Pfizer Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Pfizer Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit